Healthcare of Ontario Pension Plan Trust Fund Reduces Stock Position in Sarepta Therapeutics, Inc. $SRPT

Healthcare of Ontario Pension Plan Trust Fund lessened its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 23.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 365,329 shares of the biotechnology company’s stock after selling 113,917 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Sarepta Therapeutics were worth $7,950,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in Sarepta Therapeutics by 9.2% in the 4th quarter. Vanguard Group Inc. now owns 11,810,729 shares of the biotechnology company’s stock valued at $254,167,000 after buying an additional 993,283 shares in the last quarter. AQR Capital Management LLC raised its holdings in shares of Sarepta Therapeutics by 454.6% during the 4th quarter. AQR Capital Management LLC now owns 7,796,535 shares of the biotechnology company’s stock worth $167,781,000 after acquiring an additional 6,390,860 shares during the period. First Trust Advisors LP boosted its position in shares of Sarepta Therapeutics by 107.6% during the 1st quarter. First Trust Advisors LP now owns 4,135,788 shares of the biotechnology company’s stock valued at $89,995,000 after acquiring an additional 2,143,211 shares during the last quarter. Erste Asset Management GmbH boosted its position in shares of Sarepta Therapeutics by 1.6% during the 4th quarter. Erste Asset Management GmbH now owns 2,728,945 shares of the biotechnology company’s stock valued at $58,727,000 after acquiring an additional 43,000 shares during the last quarter. Finally, Aberdeen Group plc grew its holdings in shares of Sarepta Therapeutics by 13.6% in the fourth quarter. Aberdeen Group plc now owns 2,251,593 shares of the biotechnology company’s stock valued at $48,454,000 after purchasing an additional 268,829 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Price Performance

SRPT opened at $15.43 on Wednesday. The stock’s 50-day moving average price is $17.09 and its 200 day moving average price is $18.83. Sarepta Therapeutics, Inc. has a 12-month low of $14.68 and a 12-month high of $25.32. The firm has a market cap of $1.63 billion, a price-to-earnings ratio of -16.07, a PEG ratio of 0.17 and a beta of 0.21. The company has a current ratio of 4.63, a quick ratio of 2.62 and a debt-to-equity ratio of 0.56.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share for the quarter, beating the consensus estimate of $0.98 by $2.18. The company had revenue of $730.80 million during the quarter, compared to the consensus estimate of $474.15 million. Sarepta Therapeutics had a positive return on equity of 7.56% and a negative net margin of 2.94%.Sarepta Therapeutics’s revenue was down 1.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($3.42) EPS. As a group, sell-side analysts expect that Sarepta Therapeutics, Inc. will post 3.89 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on SRPT shares. Weiss Ratings raised shares of Sarepta Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday, July 20th. HC Wainwright reissued a “buy” rating on shares of Sarepta Therapeutics in a research note on Tuesday. Wolfe Research upgraded shares of Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 price target for the company in a report on Thursday, July 9th. Royal Bank Of Canada lifted their price target on shares of Sarepta Therapeutics from $18.00 to $19.00 and gave the company a “sector perform” rating in a research report on Tuesday, April 7th. Finally, Zacks Research lowered Sarepta Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 7th. Nine equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and six have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Sarepta Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $24.72.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.